0	1	{'start':(0, 0), 'end':(0, 12), 'text':'N-acetylgalactosaminyl transferase-3 is a potential new marker for non small cell lung cancers'}
14	31	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 12), 'text':'Lung cancer is one of the leading causes of cancer death worldwide .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(1, 0), 'end':(1, 16), 'text':'Although the management and treatment of non small cell lung cancers ( NSCLCs ) have improved ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 17), 'end':(1, 20), 'text':'there is no evidence'}, {'start':(1, 21), 'end':(1, 33), 'text':'that therapeutic advances have resulted in a marked increase of survival rates .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 13), 'text':'The overall 5-year survival rate remains at less than 15 % ( ) .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(3, 0), 'end':(3, 4), 'text':'It is not fully understood'}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 5), 'end':(3, 16), 'text':'why patients with comparable stages of NSCLC may have different clinical courses'}, {'start':(3, 17), 'end':(3, 23), 'text':'and respond differently to similar treatments .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 15), 'text':'A more sophisticated understanding of the pathogenesis and biology of these tumours could provide useful information'}, {'start':(4, 16), 'end':(4, 20), 'text':'for predicting clinical outcome ,'}]}, {'start':(4, 21), 'end':(4, 23), 'text':'individualising treatment ,'}]}, {'start':(4, 24), 'end':(4, 33), 'text':'and identifying molecular targets of the treatment ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 7), 'text':'Oligosaccharides on glycoproteins are altered in tumorigenesis .'}, {'start':(6, 0), 'end':(6, 24), 'text':'These oligosaccharides often play a role in the regulation of the biological characteristics of tumours in terms of invasion and metastatic potential ( ) .'}]}, {'start':(7, 0), 'end':(7, 10), 'text':'Each oligosaccharide is synthesised by a specific glycosyltransferase ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 5), 'text':'The initial glycosylation of mucin-type O'}, {'start':(8, 6), 'end':(8, 15), 'text':'linked proteins is catalysed by one of the UDP-N-acetyl-alpha-D-Galactosamine :'}]}, {'start':(8, 16), 'end':(8, 25), 'text':'polypeptide N-acetylgalactosaminyl transferases ( GalNAc-transferase family of enzymes ) .'}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 15), 'text':'Three distinct human GalNAc-transferases , GalNAc-T1 , GalNAc-T2 , and GalNAc-T3 , have been characterised .'}, {'start':(10, 0), 'end':(10, 16), 'text':'Recently another 3 homologue enzymes , GalNAc-T4 , GalNAc-T5 , and GalNAc-T6 , have been identified .'}]}, {'start':(11, 0), 'end':(11, 17), 'text':'Compared with the expression of GalNAc-T1 and GalNAc-T2 , the expression of GalNAc-T3 is highly tissue specific .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 6), 'text':'GalNAc-T3 mRNA has been detected in organs'}, {'start':(12, 7), 'end':(12, 12), 'text':'that contain secretory epithelial glands .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(13, 0), 'end':(13, 2), 'text':'It is hypothesised'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 3), 'end':(13, 15), 'text':'that the differential expression of GalNAc-T3 may affect the specialised functions of glycoproteins'}, {'start':(13, 16), 'end':(13, 22), 'text':'produced by normal and malignant cells ,'}]}, {'start':(13, 23), 'end':(13, 39), 'text':'and that it is also associated with biological properties of normal and malignant cells ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 23), 'text':'However , GalNAc-T3 expression has not been previously examined in human lung cancers , or in human bronchial epithelial cells and alveolar pneumocytes ,'}, {'start':(14, 24), 'end':(14, 29), 'text':'from which lung cancers develop .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 15), 'text':'In the present study , GalNAc-T3 expression was examined by immunohistochemistry in surgically resected NSCLCs .'}, {'start':(16, 0), 'end':(16, 21), 'text':'We analysed the biological and clinical importance of GalNAc-T3 expression , especially with regard to its potential as a prognostic factor .'}]}]}]}]}]}
1	14	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 7), 'text':'N-acetylgalactosaminyl transferase-3 ( GalNAc-T3 ) is an enzyme'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 8), 'end':(0, 15), 'text':'involved in the initial glycosylation of mucin-type O'}, {'start':(0, 16), 'end':(0, 18), 'text':'linked proteins .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 7), 'text':'In the present study , we used immunohistochemistry'}, {'start':(1, 8), 'end':(1, 21), 'text':'to examine GalNAc-T3 expression in 215 surgically resected non small cell lung cancers .'}]}, {'start':(2, 0), 'end':(2, 21), 'text':'We analysed the biological and clinical importance of GalNAc-T3 expression , especially with regard to its potential as a prognostic factor .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(3, 0), 'end':(3, 1), 'text':'We found'}, {'start':(3, 2), 'end':(3, 20), 'text':'that normal bronchial epithelial cells , bronchial gland cells , and alveolar pneumocytes showed cytoplasmic immunostaining for GalNAc-T3 .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 4), 'text':'Low expression of GalNAc-T3 ,'}, {'start':(4, 5), 'end':(4, 15), 'text':'observed in 93 of 215 tumours ( 43.4 % ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 16), 'end':(4, 27), 'text':'was found more frequently in tumours from smokers than those from nonsmokers'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 28), 'end':(4, 41), 'text':'( P = 0.001 ) , in squamous cell carcinomas than nonsquamous cell carcinomas'}, {'start':(4, 42), 'end':(4, 47), 'text':'( P < 0.0001 ) ,'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 48), 'end':(4, 58), 'text':'and in moderately and poorly differentiated tumours than well differentiated tumours'}, {'start':(4, 59), 'end':(4, 64), 'text':'( P = 0.0002 ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 4), 'text':'Multivariate logistic regression analysis showed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 5), 'end':(5, 27), 'text':'that an association of low GalNAc-T3 expression with squamous cell carcinomas was the only one significant relationship of GalNAc-T3 expression with various factors'}, {'start':(5, 28), 'end':(5, 33), 'text':'( P < 0.0001 ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(6, 0), 'end':(6, 2), 'text':'Moreover , tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 3), 'end':(6, 14), 'text':'losing GalNAc-T3 expression had a significantly higher Ki-67 labelling index than tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 15), 'end':(6, 17), 'text':'retaining GalNAc-T3 expression'}, {'start':(6, 18), 'end':(6, 23), 'text':'( P = 0.0003 ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 72), 'text':'Patients with low GalNAc-T3 expression survived a significantly shorter time than patients with high GalNAc-T3 expression in 103 pStage I non small cell lung cancers ( 5-year survival rates , 58 % and 78 % , respectively ; P = 0.02 by log-rank test ) as well as in 61 pStage I nonsquamous cell carcinomas ( 5-year survival rates , 63 % and 85 % , respectively ; P = 0.03 ) .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 26), 'text':'Low GalNAc-T3 expression was an unfavourable prognostic factor in pStage I non small cell lung cancers ( hazards ratio , 2.04 ; P = 0.03 ) ,'}, {'start':(8, 27), 'end':(8, 44), 'text':'and in pStage I nonsquamous cell carcinomas ( hazards ratio , 2.70 ; P = 0.03 ) .'}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 2), 'text':'These results suggest'}, {'start':(9, 3), 'end':(9, 21), 'text':'that GalNAc-T3 is a new marker of non small cell lung cancers with specificity for histology and prognosis .'}]}]}, {'start':(10, 0), 'end':(10, 10), 'text':'British Journal of Cancer ( 2002 ) 87 , 751-755 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 5), 'text':'doi :10.1038 / sj.bjc .6600536 www.bjcancer.com'}, {'start':(12, 0), 'end':(12, 6), 'text':'( c ) 2002 Cancer Research UK'}]}]}]}
97	112	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'DISCUSSION'}, {'label':'contrast', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 12), 'text':'In the present study , GalNAc-T3 expression was frequently decreased in NSCLCs ,'}, {'start':(1, 13), 'end':(1, 29), 'text':'although it was expressed in normal bronchial epithelial cells , bronchial gland cells and alveolar pneumocytes .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 14), 'text':'Furthermore , low GalNAc-T3 expression of NSCLCs was associated with a shorter survival period ,'}, {'start':(2, 15), 'end':(2, 21), 'text':'and was an unfavourable prognostic factor .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 1), 'text':'The finding'}, {'start':(3, 2), 'end':(3, 12), 'text':'that GalNAc-T3 expression was retained more frequently in nonsquamous cell carcinomas'}]}, {'start':(3, 13), 'end':(3, 13), 'text':'('}]}, {'start':(3, 14), 'end':(3, 19), 'text':'most of which were adenocarcinomas )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 20), 'end':(3, 33), 'text':'than in squamous cell carcinomas may reflect tissue specific expression of GalNAc-T3 in organs'}, {'start':(3, 34), 'end':(3, 39), 'text':'that contain secretory epithelial glands .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 16), 'text':'Moreover , in nonsquamous cell carcinomas , decreased expression of GalNAc-T3 was associated with unfavourable prognosis .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 4), 'text':'Consistent with these results ,'}, {'start':(5, 5), 'end':(5, 23), 'text':'we have recently found that GalNAc-T3 is expressed in normal epithelial cells and gland cells of the colon ,'}]}, {'start':(5, 24), 'end':(5, 42), 'text':'and that decreased expression of GalNAc-T3 is an unfavourable prognostic factor in adenocarcinomas of the colon ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 1), 'text':'The mechanism'}, {'start':(6, 2), 'end':(6, 16), 'text':'underlying the relationship between decreased GalNAc-T3 expression and poor prognosis remains to be determined .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 4), 'text':'Bronchial and alveolar epithelia ,'}, {'start':(7, 5), 'end':(7, 9), 'text':'from which NSCLCs develop ,'}]}, {'start':(7, 10), 'end':(7, 13), 'text':'normally express GalNAc-T3 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 14), 'text':'Decreased GalNAc-T3 expression may induce decreased level of glycosylation in certain types of glycoprotein ,'}, {'start':(8, 15), 'end':(8, 22), 'text':'resulting in altered functions of the glycoproteins .'}]}]}]}]}, {'start':(9, 0), 'end':(9, 16), 'text':'Therefore , the biological importance of GalNAc-T3 expression depends on the function of target substrate glycoproteins .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 15), 'text':'The importance of GalNAc-T3 expression for the development and progression of cancer as well as for'}, {'start':(10, 16), 'end':(10, 27), 'text':'maintaining physiologic properties of normal cells also remains to be determined ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 28), 'end':(10, 30), 'text':'although certain cancer'}, {'start':(10, 31), 'end':(10, 46), 'text':'associated decreases or increases in glycosylation has been shown to directly contribute to cellular transformation .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 15), 'text':'Collectively , decreased expression of GalNAc-T3 may directly contribute to altered biological properties of NSCLCs .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 0), 'end':(12, 24), 'text':'In fact , in this study , low expression of GalNAc-T3 in NSCLCs was associated with a higher LI of Ki-67 cell growth fractions ,'}, {'start':(12, 25), 'end':(12, 31), 'text':'and resulted in shorter survival times .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(13, 0), 'end':(13, 5), 'text':'In conclusion , these results indicate'}, {'start':(13, 6), 'end':(13, 20), 'text':'that GalNAc-T3 is a new marker of NSCLCs with specificity for histology and survival .'}]}]}]}, {'start':(14, 0), 'end':(14, 29), 'text':'GalNAc-T3 expression may be useful to stratify patients with pStage I tumours into groups at high and low risks of recurrence in NSCLCs , especially in nonsquamous cell carcinomas .'}]}
73	97	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'RESULTS'}, {'start':(1, 0), 'end':(1, 25), 'text':'To confirm the availability of an anti-GalNAc-T3 polyclonal antibody , Western blot analysis of a GST fusion protein ( GST-GalNAcT3N ) was performed ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 24), 'text':'Strong signals of the GST fusion protein were obtained in the immunoblotting with anti-GalNAc-T3 polyclonal antibody as well as in that with anti-GST antibody .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 12), 'text':'The specificity of this anti-GalNAc-T3 polyclonal antibody was also tested by immunohistochemistry .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 18), 'text':'After incubation of this antibody with the excess of GST-GalNAcT3N , the positive immunostaining was abolished ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 13), 'text':'Typical immunostaining patterns for GalNAc-T3 with this antibody in NSCLCs are shown in .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 19), 'text':'In tumour cells , GalNAc-T3 expression was found diffusely in the cytoplasm , or localised in the Golgi apparatus .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 17), 'text':'Normal bronchial epithelial cells ( ) , bronchial gland cells ( ) , and alveolar pneumocytes ( data'}, {'start':(7, 18), 'end':(7, 20), 'text':'not shown )'}]}, {'start':(7, 21), 'end':(7, 24), 'text':'also expressed GalNAc-T3 .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 14), 'text':'Of the 215 NSCLCs , 122 ( 56.7 % ) had high GalNAc-T3 expression ,'}, {'start':(8, 15), 'end':(8, 27), 'text':'and 93 ( 43.3 % ) had low GalNAc-T3 expression ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 19), 'text':'The status of GalNAc-T3 expression was statistically analysed to investigate possible correlations with clinical and clinicopathological characteristics of NSCLCs .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 16), 'text':'Low expression of GalNAc-T3 was significantly more prevalent in tumours from men than in those from women'}, {'start':(10, 17), 'end':(10, 26), 'text':'( P = 0.0001 by the chi 2 test )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 27), 'end':(10, 31), 'text':'and in tumours from smokers'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 32), 'end':(10, 34), 'text':'compared to nonsmokers'}, {'start':(10, 35), 'end':(10, 40), 'text':'( P = 0.001 ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 14), 'text':'Low GalNAc-T3 expression was also more prevalent in squamous cell carcinomas than nonsquamous cell carcinomas'}, {'start':(11, 15), 'end':(11, 22), 'text':'( P < 0.0001 ) ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 10), 'text':'GalNAc-T3 expression was not associated with pTNM classifications and pStage .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 22), 'text':'Multivariate logistic regression analysis showed a significant association of low GalNAc-T3 expression with squamous cell ( P < 0.0001 ) ( ) .'}, {'start':(14, 0), 'end':(14, 25), 'text':'This relationship between GalNAc-T3 expression and histology was the only significant relationship between GalNAc-T3 expression and various factors within the context of the multivariate model .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(15, 0), 'end':(15, 4), 'text':'Tumours having low GalNAc-T3 expression'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 5), 'end':(15, 12), 'text':'showed a significantly higher Ki-67 LI than tumours'}, {'start':(15, 13), 'end':(15, 24), 'text':'having high GalNAc-T3 expression ( P = 0.0003 ) ( ) .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 14), 'text':'Tumours having low GalNAc-T3 expression also exhibited a high Ki-67 LI more frequently than tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 15), 'end':(16, 18), 'text':'having high GalNAc-T3 expression'}, {'start':(16, 19), 'end':(16, 24), 'text':'( P = 0.0003 ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 11), 'text':'We analysed the relationship between GalNAc-T3 expression and postsurgical survival in pStage'}, {'start':(17, 12), 'end':(17, 16), 'text':'I NSCLCs ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(18, 0), 'end':(18, 9), 'text':'When the 103 pStage I NSCLCs were evaluated together ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 10), 'end':(18, 12), 'text':'patients with tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 13), 'end':(18, 25), 'text':'having low GalNAc-T3 expression survived a significantly shorter time than patients with tumours'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 26), 'end':(18, 28), 'text':'having high expression'}, {'start':(18, 29), 'end':(18, 46), 'text':'( 5-year survival rates , 58 % and 78 % , respectively , by the Kaplan-Meier method ;'}]}, {'start':(18, 47), 'end':(18, 58), 'text':'P = 0.02 by the generalised Wilcoxon test ) ( ) .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(19, 0), 'end':(19, 10), 'text':'When only patients with 43 squamous cell carcinomas were analysed ,'}, {'start':(19, 11), 'end':(19, 37), 'text':'GalNAc-T3 expression did not show a significant effect on survival ( 5-year survival rates , 54 % for low GalNAc-T3 and 57 % for high GalNAc-T3 ;'}]}, {'start':(19, 38), 'end':(19, 42), 'text':'P = 0.8 ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 9), 'text':'Among 61 nonsquamous cell carcinoma patients , patients with tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 10), 'end':(20, 22), 'text':'having low GalNAc-T3 expression survived a significantly shorter time than patients with tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 23), 'end':(20, 25), 'text':'having high expression'}, {'start':(20, 26), 'end':(20, 45), 'text':'( 5-year survival rates , 63 % and 85 % , respectively ; P = 0.03 ) ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 21), 'text':'The importance of GalNAc-T3 as a prognostic factor was analysed by the Cox \'s proportional hazards model analysis in patients with pStage'}, {'start':(21, 22), 'end':(21, 26), 'text':'I NSCLCs ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(22, 0), 'end':(22, 6), 'text':'Univariate analysis of potential prognostic factors revealed'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 7), 'end':(22, 22), 'text':'that low expression of GalNAc-T3 was the only statistically significant unfavourable prognostic factor in overall NSCLCs'}, {'start':(22, 23), 'end':(22, 32), 'text':'( hazards ratio , 2.04 ; P = 0.03 )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 33), 'end':(22, 37), 'text':'and in nonsquamous cell carcinomas'}, {'start':(22, 38), 'end':(22, 48), 'text':'( hazards ratio , 2.70 ; P = 0.03 ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 10), 'text':'GalNAC-T3 expression was not a prognostic factor in squamous cell carcinomas'}, {'start':(23, 11), 'end':(23, 21), 'text':'( hazards ratio , 0.91 ; P = 0.8 ) .'}]}]}]}]}]}
31	73	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 2), 'text':'MATERIALS AND METHODS'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 4), 'text':'Tumour specimens and survival data'}, {'start':(2, 0), 'end':(2, 21), 'text':'Primary tumour specimens from 215 NSCLCs were consecutively obtained by surgery from the Hokkaido University Medical Hospital during 1976 and 1994 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 11), 'text':'The patients with NSCLCs consisted of 142 men and 73 women .'}, {'start':(4, 0), 'end':(4, 16), 'text':'The histologic classification of the tumour specimens was based on World Health Organization criteria ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 22), 'text':'The tumour specimens included 87 squamous cell carcinomas , 110 adenocarcinomas , nine large cell carcinomas , and eight adenosquamous cell carcinomas .'}, {'start':(6, 0), 'end':(6, 13), 'text':'Nonsquamous cell carcinoma included adenocarcinoma , large cell carcinoma and adenosquamous cell carcinoma .'}]}]}, {'start':(7, 0), 'end':(7, 23), 'text':'There were 119 Stage I , 18 Stage II , 70 Stage IIIa , one Stage IIIb , and seven Stage IV tumours .'}]}, {'start':(8, 0), 'end':(8, 23), 'text':'The postsurgical pathologic TNM stage ( pTNM ) was determined according to the guidelines of the American Joint Committee on Cancer ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 19), 'text':'Of the 119 patients with pStage I tumours resected with curative intent , survival was analysed for the 103 patients'}, {'start':(9, 20), 'end':(9, 25), 'text':'who met the following criteria :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 26), 'end':(9, 37), 'text':'( 1 ) survived for more than 3 months after surgery ;'}, {'start':(9, 38), 'end':(9, 55), 'text':'( 2 ) did not die of causes other than lung cancer within 5 years after surgery ;'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 56), 'end':(9, 71), 'text':'and ( 3 ) were followed for more than 3 years after surgery ( for patients'}, {'start':(9, 72), 'end':(9, 76), 'text':'who remained alive ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 7), 'text':'Sixteen patients did not meet the above criteria'}, {'start':(10, 8), 'end':(10, 8), 'text':'('}]}, {'start':(10, 9), 'end':(10, 16), 'text':'four died within 3 months after surgery ,'}]}, {'start':(10, 17), 'end':(10, 28), 'text':'five died of causes other than lung cancer within 5 years ,'}]}, {'start':(10, 29), 'end':(10, 37), 'text':'and seven had no survival records after surgery )'}]}, {'start':(10, 38), 'end':(10, 44), 'text':'were excluded from the survival analysis .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'temporal', 'direction':'RightToLeft', 'children':[{'start':(11, 0), 'end':(11, 9), 'text':'Of the 103 patients for whom survival was analysed ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 10), 'end':(11, 16), 'text':'54 patients had died of cancer ,'}, {'start':(11, 17), 'end':(11, 39), 'text':'including 27 with squamous cell carcinomas , 22 with adenocarcinomas , three with large cell carcinomas and two with adenosquamous cell carcinomas .'}]}]}, {'start':(12, 0), 'end':(12, 14), 'text':'The Karnofsky performance status was 90 % or greater in all these 103 patients .'}]}, {'start':(13, 0), 'end':(13, 15), 'text':'This study was approved by the Medical Ethical Committees of Hokkaido University School of Medicine .'}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(14, 0), 'end':(14, 5), 'text':'Because all patients were coded ,'}, {'start':(14, 6), 'end':(14, 12), 'text':'they could not be individually identified .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 9), 'text':'Construction of the plasmid and preparation of GST fusion protein'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 32), 'text':'The GalNAcT3 cDNA was cloned into pGEM-Teasy ( Promega , Madison , WI , USA ) by RT-PCR using the primers 5 \' - ATGGCTCACCTAAAGCGACTAG-3 \' and 5 \' - GAAAGACTCCAGTCAAAATTTCC-3 \' ,'}, {'start':(16, 33), 'end':(16, 38), 'text':'as described previously ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(17, 0), 'end':(17, 14), 'text':'The EcoRI-Eco47III fragment ( amino acid residues 1-178 of the whole 324 amino acids )'}, {'start':(17, 15), 'end':(17, 23), 'text':'was cloned into EcoRI-SmaI sites in the pGEX-6P ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 24), 'end':(17, 38), 'text':'and GST fusion protein ( GST-GalNAcT3N ) was purified according to the manufacturer \'s protocol'}, {'start':(17, 39), 'end':(17, 46), 'text':'( Pharmacia , Uppsala , Sweden ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 6), 'text':'Western blot analysis of GST fusion protein'}, {'label':'joint', 'direction':'None', 'children':[{'start':(19, 0), 'end':(19, 11), 'text':'Both GST and GST-GalNAcT3N were separated on a 12 % SDS-PAGE gel'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 12), 'end':(19, 17), 'text':'and transferred to polyvinylidene difluoride membrane'}, {'start':(19, 18), 'end':(19, 26), 'text':'( Millipore , Bedford , MA , USA )'}]}, {'start':(19, 27), 'end':(19, 30), 'text':'using semidry blotter .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 22), 'text':'Immunoblot analysis was performed with anti-GST antibody ( Santa Cruz Biotechnology , Santa Cruz , CA , USA ) and anti-GalNAcT3 antibody ,'}, {'start':(20, 23), 'end':(20, 37), 'text':'which was a rabbit polyclonal antibody against a synthesised peptide of human GalNAc-T3 ( )'}]}, {'start':(20, 38), 'end':(20, 43), 'text':'and was used for immunohistochemistry .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 3), 'text':'Immunohistochemistry for GalNAc-T3 expression'}, {'start':(22, 0), 'end':(22, 6), 'text':'GalNAc-T3 expression was analysed by immunohistochemistry .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 11), 'text':'The labelled streptavidin biotin method was used on 4-mum sections of formalin'}, {'start':(23, 12), 'end':(23, 19), 'text':'fixed , paraffin embedded tissues after deparaffinisation .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 11), 'text':'Briefly , deparaffinised tissue sections were microwaved twice in 10mM citrate buffer'}, {'start':(24, 12), 'end':(24, 15), 'text':'( pH6 .0 )'}]}, {'start':(24, 16), 'end':(24, 22), 'text':'for 5min to retrieve the antigenicity .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 7), 'text':'The sections were incubated with normal rabbit serum'}, {'start':(25, 8), 'end':(25, 16), 'text':'to block the non specific antibody binding sites .'}]}, {'start':(26, 0), 'end':(26, 32), 'text':'The sections were then incubated with a 1:5000 dilution of rabbit polyclonal antibody against a synthesised peptide of human GalNAc-T3 ( ) or with control rabbit non immunised serum at 4degreesC overnight .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 26), 'text':'Immunostaining was performed by the biotin-streptavidin immunoperoxidase method with 3,3 \' - diaminobenzidine as a chromogen ( SAB-PO kit ; Nichirei , Tokyo , Japan ) .'}, {'start':(28, 0), 'end':(28, 6), 'text':'Sections were counterstained with methyl green .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 25), 'text':'GalNAc-T3 expression in normal bronchial epithelial cells , bronchial gland cells , and alveolar pneumocytes in the same sections served as an internal positive control .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 11), 'text':'The GalNAc-T3 expression in tumours was classified as high or low ,'}, {'start':(30, 12), 'end':(30, 21), 'text':'according to the proportion of positively stained tumour cells .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(31, 0), 'end':(31, 11), 'text':'Tumours with staining in at least 50 % of cancer cells ,'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(31, 12), 'end':(31, 13), 'text':'were judged'}, {'start':(31, 14), 'end':(31, 25), 'text':'as having high GalNAc-T3 expression ( retaining expression of GalNAc-T3 ) .'}]}]}, {'label':'background', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(32, 0), 'end':(32, 11), 'text':'Tumours with staining in less than 50 % of cancer cells ,'}, {'start':(32, 12), 'end':(32, 13), 'text':'were judged'}]}, {'start':(32, 14), 'end':(32, 25), 'text':'as having low GalNAc-T3 expression ( losing expression of GalNAc-T3 ) ,'}]}, {'start':(32, 26), 'end':(32, 32), 'text':'as we previously described ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 6), 'text':'For the Ki-67 staining , the results'}, {'start':(33, 7), 'end':(33, 12), 'text':'that were previously reported ( )'}]}, {'start':(33, 13), 'end':(33, 19), 'text':'were used for the present study .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 1), 'text':'Statistical analysis'}, {'start':(35, 0), 'end':(35, 22), 'text':'The associations between GalNAc-T3 expression and categorical variables were analysed by the chi 2 test or Fisher \'s exact test as appropriate .'}]}]}]}, {'start':(36, 0), 'end':(36, 21), 'text':'The associations between GalNAc-T3 expression and age or the Ki-67 labelling index ( LI ) were analysed by Student \'s t-test .'}]}, {'start':(37, 0), 'end':(37, 22), 'text':'To simultaneously examine the effect of more than one factor on GalNAc-T3 expression , multivariate logistic regression analysis was used ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 4), 'text':'The survival curves were estimated'}, {'label':'joint', 'direction':'None', 'children':[{'start':(38, 5), 'end':(38, 9), 'text':'using the Kaplan-Meier method ,'}, {'start':(38, 10), 'end':(38, 22), 'text':'and differences in survival distributions were evaluated by the generalised Wilcoxon test .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 22), 'text':'Cox \'s proportional hazards modelling of factors potentially related to survival was performed to identify factors with a significant influence on survival .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 9), 'text':'P values less than 0.05 were considered statistically significant .'}, {'start':(41, 0), 'end':(41, 5), 'text':'All tests were two sided .'}]}]}]}]}]}]}
